168 related articles for article (PubMed ID: 33094837)
1. Atraumatic bone pain in multiple myeloma secondary to bisphosphonate-related bone injury.
Williams R; Wolger L; Alajangi R
Br J Haematol; 2021 Jan; 192(2):229. PubMed ID: 33094837
[No Abstract] [Full Text] [Related]
2. Bisphosphonate therapy in the treatment of multiple myeloma.
Lawson MA; Ashcroft J; Croucher PI
Curr Pharm Des; 2010; 16(27):3028-36. PubMed ID: 20722619
[TBL] [Abstract][Full Text] [Related]
3. Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy.
Chang ST; Tenforde AS; Grimsrud CD; O'Ryan FS; Gonzalez JR; Baer DM; Chandra M; Lo JC
Bone; 2012 Sep; 51(3):524-7. PubMed ID: 22634175
[TBL] [Abstract][Full Text] [Related]
4. [Multiple myeloma].
Abe M
Nihon Rinsho; 2009 May; 67(5):991-5. PubMed ID: 19432122
[TBL] [Abstract][Full Text] [Related]
5. Further analyses of the Myeloma IX Study.
Morgan GJ
Lancet; 2011 Aug; 378(9793):768-9. PubMed ID: 21872746
[No Abstract] [Full Text] [Related]
6. Skull base osteomyelitis and bisphosphonate use in multiple myeloma: report of two cases and literature review.
Phillips JM; Thibodeaux JD; Nathan C
Laryngoscope; 2010; 120 Suppl 4():S175. PubMed ID: 21225773
[TBL] [Abstract][Full Text] [Related]
7. Atraumatic bilateral femur fracture in long-term bisphosphonate use.
Yli-Kyyny TT; Tamminen I; Kröger H
Orthopedics; 2010 Dec; 33(12):867. PubMed ID: 21117559
[No Abstract] [Full Text] [Related]
8. Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate.
Lobato JV; Maurício AC; Rodrigues JM; Cavaleiro MV; Cortez PP; Xavier L; Botelho C; Hussain NS; Santos JD
J Plast Reconstr Aesthet Surg; 2008; 61(1):99-106. PubMed ID: 18068658
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic role of bisphosphonate and radiation combination in the management of myeloma bone disease.
Ural AU; Avcu F
Clin Cancer Res; 2007 Jun; 13(11):3432. PubMed ID: 17545554
[No Abstract] [Full Text] [Related]
10. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series.
Fedele S; Porter SR; D'Aiuto F; Aljohani S; Vescovi P; Manfredi M; Arduino PG; Broccoletti R; Musciotto A; Di Fede O; Lazarovici TS; Campisi G; Yarom N
Am J Med; 2010 Nov; 123(11):1060-4. PubMed ID: 20851366
[TBL] [Abstract][Full Text] [Related]
11. Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates.
Pochintesta L; Mangiacavalli S; Cocito F; Pompa A; Albertini R; Pascutto C; Ferretti VV; Cazzola M; Corso A
Leuk Lymphoma; 2014 Jun; 55(6):1397-8. PubMed ID: 23931337
[No Abstract] [Full Text] [Related]
12. Bisphosphonates in multiple myeloma.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2010 Mar; (3):CD003188. PubMed ID: 20238320
[TBL] [Abstract][Full Text] [Related]
13. Radiology quiz case. Osteonecrosis of the jaw: aminobisphosphonate epidemic.
Junquera L; Gallego L; Villarreal P
Arch Otolaryngol Head Neck Surg; 2008 Nov; 134(11):1229-31. PubMed ID: 19015457
[No Abstract] [Full Text] [Related]
14. Bisphosphonate-induced osteonecrosis of the jaw: long-term outcomes.
Katz J; George T; Sandow P; Machado M; Dickerson L; Moreb JS
J Support Oncol; 2009; 7(1):9-10. PubMed ID: 19278171
[No Abstract] [Full Text] [Related]
15. Bisphosphonates--role in cancer therapies.
Mehrotra B
J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
[No Abstract] [Full Text] [Related]
16. Optimal use of bisphosphonates in patients with multiple myeloma.
Terpos E; Roodman GD; Dimopoulos MA
Blood; 2013 Apr; 121(17):3325-8. PubMed ID: 23407550
[No Abstract] [Full Text] [Related]
17. Bisphosphonate complications including osteonecrosis of the jaw.
Mehrotra B; Ruggiero S
Hematology Am Soc Hematol Educ Program; 2006; ():356-60, 515. PubMed ID: 17124083
[TBL] [Abstract][Full Text] [Related]
18. The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates.
Kraj M; Pogłód R; Maj S; Owczarska K
Acta Pol Pharm; 2006; 63(5):450-2. PubMed ID: 17357613
[No Abstract] [Full Text] [Related]
19. Bone Disease in Myeloma: The Claws of CRAB.
Fonseca R; Jain T
Clin Cancer Res; 2016 Mar; 22(6):1301-3. PubMed ID: 26792259
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate-induced osteonecrosis of the jaw 32 months after interruption of zoledronate in a patient with multiple myeloma.
Del Conte A; Bernardeschi P; La Ferla F; Turrisi G; D'Alessandro M; Montagnani F; Fiorentini G
J Oral Maxillofac Surg; 2010 May; 68(5):1179-82. PubMed ID: 20185222
[No Abstract] [Full Text] [Related]
[Next] [New Search]
